Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Bacillus anthracis | Anthrax lethal factor | Starlite/ChEMBL | No references |
Homo sapiens | euchromatic histone-lysine N-methyltransferase 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.0665 | 0.0665 |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.0128 | 0.3019 | 0.2989 |
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.0128 | 0.3019 | 0.3019 |
Onchocerca volvulus | 0.0286 | 0.8153 | 1 | |
Schistosoma mansoni | thyroid hormone receptor | 0.0138 | 0.3352 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.005 | 0.0502 | 0.0657 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.0665 | 0.0891 |
Toxoplasma gondii | histone lysine methyltransferase SET/SUV39 | 0.0036 | 0.0043 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0128 | 0.3019 | 0.8994 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.005 | 0.0502 | 0.1388 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.0665 | 0.0665 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0665 | 0.1881 |
Brugia malayi | Pre-SET motif family protein | 0.0251 | 0.7026 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0665 | 0.1881 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0665 | 0.1881 |
Schistosoma mansoni | thyroid hormone receptor | 0.0138 | 0.3352 | 1 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0251 | 0.7026 | 1 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0138 | 0.3352 | 0.3323 |
Echinococcus multilocularis | tumor protein p63 | 0.0343 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.0665 | 0.0625 |
Echinococcus granulosus | histone lysine methyltransferase setb | 0.0036 | 0.0043 | 0.0043 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.0665 | 0.0625 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.0665 | 0.0891 |
Plasmodium vivax | SET domain protein, putative | 0.0036 | 0.0043 | 0.5 |
Onchocerca volvulus | 0.005 | 0.0502 | 0.0566 | |
Trichomonas vaginalis | set domain proteins, putative | 0.0286 | 0.8153 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | = 5.0119 um | PUBCHEM_BIOASSAY: qHTS Assay for Anthrax Lethal Toxin Internalization. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.